You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《藍籌業績》中國生物製藥(01177.HK)全年純利27.1億人幣跌70.1% 派末期息2港仙
阿思達克 03-30 16:31
中國生物製藥(01177.HK)公布截至去年12月底止全年業績,營業額242.34億元人民幣(下同),按年升16%。僅因缺少上年錄得之大額一次性分階段收購收益,純利按年跌70.1%至27.07億元,;每股盈利21.58分。派末期息2港仙,按年持平。連同已派發首三季股息,全年合共派發股息每股8港仙。

期內,基本盈利為31.32億元,按年增長10.2%;每股基本盈利24.97分,按年增長8.7%。

於去年,肝病用藥銷售額約幣57.4億元,佔集團收入23.7%;抗腫瘤用藥之銷售額約54.3億元,佔收入約22.4%;心腦血管用藥之銷售額約31.2億元,佔收入約12.9%。另外,新產品銷售佔集團去年總收入約20.7%。

去年集團研究及開發費為20.9億元升至23.99億元,及記錄為發展成本之資本化研發金額約2.53億元,合共佔集團收入約10.9%。

集團去年獲得生產批件28件,19個產品獲批一致性評價。獲得臨床批件23件。新申報生產25件,新申報臨床19件,新申報受理一致性評價26件。此外,集團新獲得發明專利授權83件,新提交發明專利申請341件。

集團指,去年先後有5個原優勢品種在兩輪集中帶量採購中中標,受降價幅度影響,銷售業績和利潤未達預期;凱時獲列入國家輔助用藥目錄對銷售影響較大,銷售業績下滑;但集中採購使集團得以將更多資源用於加強研發,學術推廣更專注於抗腫瘤產品和競爭較小的其他新產品。(ek/k)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account